Pliant Therapeutics Q2 net loss $29.5M; pro-forma cash $379.8M after $215.7M offering

PLIANT THERAPEUTICS, INC.

2022-Q2 EPS reported -$1.59 revenue$6,238,000

Net loss of $29.5M in Q2 2022 vs $22.8M in prior-year quarter; R&D expenses $26.3M (up from $19.2M).
Pro-forma cash, cash equivalents and short-term investments of $379.8M as of June 30, 2022.
PLN-74809 INTEGRIS-IPF Phase 2a met primary endpoint; dose-dependent effects on FVC and QLF observed.
FDA Fast Track designation for PLN-74809 in PSC; topline data from INTEGRIS-PSC expected H1 2023.
Received $4.0M milestone from Novartis collaboration; loan facility with Oxford Finance provides up to $100M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.